Jia Yi-Qun, Yang Bo, Wen Li-Ling, Mu Wen-Xin, Wang Zhi, Cheng Bin
Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong 510055, China.
Aging (Albany NY). 2019 Jan 22;11(2):501-522. doi: 10.18632/aging.101756.
Immune checkpoint molecules are important targets in cancer immunotherapy, but their association with prognosis in patients with head and neck cancer is controversial. In this meta-analysis, we searched for 12 immune checkpoint molecules in the PubMed, Embase and Cochrane Library databases and retrieved 52 studies with 7127 participants. Among the molecules included in the search, indoleamine 2, 3-dioxygenase (IDO), programmed death ligand 1 (PD-L1), and programmed death 1 (PD-1) met the inclusion criteria for further analysis. Higher expression of IDO was associated with poorer overall survival in head and neck cancer patients ( = 0.011), but higher expression of PD-L1 correlated with better overall survival specifically in nasopharyngeal carcinoma patients ( = 0.01). In a sensitivity analysis, higher PD-L1 expression correlated with better progression-free survival ( = 0.043), and was associated with better overall survival in Caucasian subjects ( = 0.02), nasopharyngeal carcinoma patients ( = 0.015), and studies with small sample sizes ( = 0.001). PD-1 had no prognostic significance. There was no publication bias affecting the results. Thus, among the immune checkpoint molecules, IDO and PD-L1 are potential prognostic predictors in head and neck cancer.
免疫检查点分子是癌症免疫治疗中的重要靶点，但其与头颈癌患者预后的相关性仍存在争议。在这项荟萃分析中，我们在PubMed、Embase和Cochrane图书馆数据库中检索了12种免疫检查点分子，并检索到52项研究，共7127名参与者。在所检索的分子中，吲哚胺2,3-双加氧酶（IDO）、程序性死亡配体1（PD-L1）和程序性死亡1（PD-1）符合进一步分析的纳入标准。IDO表达较高与头颈癌患者较差的总生存期相关（P = 0.011），但PD-L1表达较高与鼻咽癌患者较好的总生存期相关（P = 0.01）。在敏感性分析中，较高的PD-L1表达与较好的无进展生存期相关（P = 0.043），并与白种人受试者（P = 0.02）、鼻咽癌患者（P = 0.015）和小样本量研究（P = 0.001）的较好总生存期相关。PD-1没有预后意义。没有出版偏倚影响结果。因此，在免疫检查点分子中，IDO和PD-L1是头颈癌潜在的预后预测指标。
Zotero 插件
